Bioceres Crop Solutions (BIOX) Q3 2025 earnings summary

Executive summary

• Fiscal Q3 was seasonally slow, with total revenues of $60.6 million, down 28% year-over-year, mainly due to the absence of last year's $15.7 million Syngenta upfront payment accrual.

• Net cash flow from operating activities improved by $40.7 million year-over-year, reaching $23.3 million, driven by working capital efficiencies and seed business reorganization.

• Adjusted EBITDA was $9.0 million, down from $21.1 million, with a net loss of $1.6 million compared to net income of $9.8 million in 3Q24.

• Strategic focus on biologicals, with EPA approval of Rinotec, positioning for future growth and integrated pest management offerings.

Financial highlights

• Revenue declined to $60.6 million from $84 million in 3Q24, primarily due to the prior year’s Syngenta payment.

• Gross profit fell 44% year-over-year to $23.8 million; gross margin declined from 51% to 39%, explained by the Syngenta effect.

• Adjusted EBITDA dropped to $9.0 million from $21.1 million, mainly due to the Syngenta payment impact.

• Net loss for the period was $1.6 million, compared to a profit of $9.8 million in 3Q24.

• Cash position at quarter-end was nearly $40 million, up both year-over-year and sequentially.

Outlook and guidance

• Expecting an additional $10 million working capital benefit from further seed business transition.

• Aiming to return to historical EBITDA margins of ~25% and gross margins in the high 40s to 50%.

• Anticipate further operational leverage and cost savings from ongoing restructuring, with $5 million annualized savings from payroll and structural cost reductions.

• Strategic focus on expanding platform presence in Brazil, US, Mexico, and the EU, leveraging innovation from technology platforms for FY26-28.

• Market introduction of Rinotec platform in the US and Brazil expected to begin in FY26, supported by regulatory approvals and partnerships.